Medtronic plc
Medtronic Reports FY26 Q1 Financial Results and New Board Appointments
Summary
Medtronic plc announced its first quarter fiscal year 2026 financial results, showing organic revenue growth of 4.8%. The company also reported non-GAAP diluted EPS of $1.26, up 2% from the prior year. Additionally, the Board of Directors expanded from 11 to 13 members with the appointment of John Groetelaars and William Jellison, effective August 19, 2025.
Profitelligence Alerts
Get alerts for MDT
Be first to know when Medtronic plc files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Medtronic plc
Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.
Official SEC Documents
Advertisement